IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
IceCure Medical highlighted a new peer-reviewed article in the International Journal of Surgery, ranked third globally, demonstrating ProSense cryoablation's clinical advantages over radiofrequency ablation for early-stage breast cancer. The publication cites data showing a 99.02% recurrence-free rate with cryoablation compared to 98.6% for RFA, while noting benefits such as the use of local anesthesia and visible ice ball margins.
Key figures
- Follow up years max
- 17
- Recurrence free rate rfa
- 98.6%
- Procedures performed fukuma
- 680
- Recurrence free rate cryoablation
- 99.02%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.